Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926994 | 0.89 | FYN (0.36) | FYNKDM4EALDH1A1HPGDIKBKB | |
| SCHEMBL14927047 | 0.72 | FYN (0.38) | FYNKDM4EALDH1A1HPGDEGFR | |
| SCHEMBL16510635 | 0.71 | FYN (0.32) | FYN | |
| SCHEMBL12070670 | 0.67 | PTAFR (0.58) | FYN | |
| SCHEMBL14930719 | 0.66 | FYN (0.40) | FYNKDM4EALDH1A1BMPR1ATGFBR1 | |
| SCHEMBL12075016 | 0.64 | PDGFRB (0.73) | FYNALDH1A1 | |
| Methoxy Aucuparin SCHEMBL8420787 | 0.63 | KDM4E (0.62) | FYNKDM4EALDH1A1HPGDACHE | |
| SCHEMBL14906859 | 0.63 | PTAFR (0.45) | FYNTGFBR1ACVR1 | |
| SCHEMBL28338665 | 0.62 | HPGD (0.61) | FYNKDM4EALDH1A1HPGDACHE | |
| SCHEMBL12072009 | 0.62 | CTDSP1 (0.46) | FYNKDM4EALDH1A1HPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | disclosed |
| WO-2011156626-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | FYN 3983/4885KDM4E 2572/4885ALDH1A1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.